ClinicalTrials.gg
Active, not recruitingNCT04341571Updated Oct 7, 2026

Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.

A Phase 2 interventional study of Probiotics and Metformin in PreDiabetes, Impaired Glucose Tolerance and Hyperglycemia, sponsored by University of Guadalajara. Active, not recruiting at 1 site in Mexico. Open to participants aged 31 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Guadalajara · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2019, registered Apr 2020).
Updated Oct 7, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
31 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing metformin in Prediabetic State — 2 open to participants now, 4 under way, none of them phase 3. Metformin · Prediabetic State.

Planned enrollment
24th of 33
30 · median 46
Started
2019
with 3 others
Phase 2
4 of 33
none open now
Registered
25th of 33
by date
Lead sponsor
3 of 33
University of Guadalajara

Among the 33 studies testing metformin in Prediabetic State, this one is the 24th largest by planned enrollment, is one of 4 that started in 2019, is one of 4 in phase 2, and was the 25th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

2 of the 33 studies testing metformin in Prediabetic State are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 31 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing metformin in Prediabetic State, or all of them as a file.
02

Study summary

Pre diabetes (PD) is a term that refers to alterations in blood glucose levels, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, and increase in glycated hemoglobin (HbA1c), all this factors involving a higher risk to develop type 2 diabetes mellitus (T2DM).

The efficacy of pharmacotherapy in the prevention of diabetes in adults with pre diabetes has been demonstrated, the first line of pharmacology treatment is metformin, on the other hand, probiotics administration has been reported to be one of the most widely used approaches to modulate the gut microbiota and subsequently prevent or delay the incidence of T2DM.

Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. Has been demonstrated the hypoglycemic effects of the probiotics in different clinical trials in type 2 diabetes mellitus and pre diabetes, but no yet compared with metformin, for this reason comparing it´s activity against metformin in pre diabetes would provide impact information on a new alternative treatment compared with the standard pharmacological treatment.

The aim of the study is evaluate the effect of administration of probiotic versus metformin on glycemic control, insulin secretion and insulin sensitivity in patients with pre diabetes.

Read the detailed description

A randomized, double-blind controlled clinical trial in 30 patients between 31 to 60 years of age with a diagnosis of prediabetes (IFG 100 a 125 mg/dL, IGT 140 a 199 mg/dL, HbA1c 5.7 a 6.4%) in accordance with the American Diabetes Association without treatment.

Patients with one or more of the following criteria will be excluded: History of liver, kidney or heart disease; systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, HbA1c ≥6.5%, triglycerides ≥ 400 mg/dL, total cholesterol ≥240 mg/dL; pregnancy or lactation; consumption of medications or supplements with effects on glucose levels.

They will be assigned randomly two groups of 15 patients; one of the groups will receive 750 mg of metformin twice at day (before breakfast and dinner) for 13 weeks.

The other group will receive 400 mg of probiotics 1 time at day (before breakfast) and placebo pill (before dinner) for 13 weeks.

They will be measured fasting blood glucose, postprandial glucose levels and glycosylated hemoglobin, and will be calculated area under curve of glucose an insulin, total insulin secretion (Insolinogenic index), first-phase of insulin secretion (Strumvoll index) and insulin sensitivity (Matsuda index).

This protocol It´s already approved by the local ethics committee and written informed consent it´s going to be obtained from all volunteers.

Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentage for qualitative variable. Will be used Wilcoxon range test for identification of differences between baseline and final evaluation of each intervention group, Mann-Whitney U Test and Wilcoxon Test for the within-groups differences. It will be considered satitistical significance p >0.05.

03

Conditions studied

  • PreDiabetes
  • Impaired Glucose Tolerance
  • Hyperglycemia
  • Resistance, Insulin

Keywords

  • Probiotics
  • Prediabetes
  • Hyperglycemia
  • Impaired Fasting Glucose
  • Glucose intolerance
  • Metformin
04

Who can participate

Ages eligible
31 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients both sexes
  • Age between 31 and 60 years
  • Diagnosis of prediabetes according ADA criteria (fasting blood glucose levels between 100-125 mg/dL, postprandial blood glucose levels after an oral glucose tolerance test with 75 g of oral glucose between 140-199 mg/dL and between 5.7-6.4 %)
  • from 25 to 34.9 kg/m2
  • Stable weight at least the previous last 3 months (weight variation less than 10%)
  • Acceptance and signing of

Exclusion criteria

Exclusion Criteria:

  • History of kidney, liver or heart disease
  • Women with confirmed or suspected pregnancy
  • Women under lactation and/or puerperium
  • Physical impossibility for taking pills
  • Hypersensibility to ingredients of intervention
  • Consumption of medications or supplements with effects on glucose levels
  • Systolic blood pressure ≥ 140 mmHg
  • Diastolic blood pressure ≥ 90 mmHg
  • ≥6.5%
  • Triglycerides ≥ 400 mg/dL
  • Total cholesterol ≥ 240 mg/dL
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Probiotics

    15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.

    Dietary Supplement: Probiotics

  • Experimental
    Metformin

    15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.

    Drug: Metformin

Interventions

  • Dietary supplementProbiotics

    Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.

  • Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks. Homologated to the other intervention.

06

What researchers measure

Primary outcomes

  1. Fasting glucose levels

    The fasting glucose levels will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get fasting glucose level

    Time frame: Baseline to week 13 (end of intervention)

  2. Postpandrial glucose levels

    Glucose will be evaluated at baseline and week 13 after a oral glucose tolerance test with enzymatic-colorimetric technique

    Time frame: Baseline to week 13 (end of intervention)

  3. Glycosylated hemoglobin

    Glycosylated hemoglobin will be evaluated at baseline and week 13 by high efficiency liquid chromatography.

    Time frame: Baseline to week 13 (end of intervention)

  4. Insulin sensitivity

    Insulin sensitivity will be calculated at baseline and week 13 with Matsuda index to get insuline sensitivity

    Time frame: Baseline to week 13 (end of intervention)

  5. Total insulin secretion

    Total insulin secretion will be calculated at baseline and week 13 with Insulinogenic index to get total insulin secretion

    Time frame: Baseline to week 13 (end of intervention)

  6. First phase of insuline secretion

    The first phase if insuline secretion will be calculated at baseline and week 13 with Stumvoll index to get first phase of insuline secretion

    Time frame: Baseline to week 13 (end of intervention)

Secondary outcomes

  1. Body weight

    Body weight will be measured at baseline and week 13 with a bioimpedance balance

    Time frame: Baseline to week 13 (end of intervention)

  2. Body mass index (BMI)

    Body mass index will be calculated at baseline and week 13 with the Quetelet index formula

    Time frame: Baseline to week 13 (end of intervention)

  3. Waist circunference

    Waist circunference will be evaluated at baseline and week 13 by World Health Organization technique

    Time frame: Baseline to week 13 (end of intervention)

  4. Blood pressure

    Systolic blood pressure and diastolyc blood pressure will be measured at baseline and week 13 with a digital sphygmomanometer three times in each arm to get an average

    Time frame: Baseline to week 13 (end of intervention)

  5. Total cholesterol

    Total chilesterol level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get total cholesterol level

    Time frame: Baseline to week 13 (end of intervention)

  6. High density lipoprotein (c-HDL)

    High density lipoprotein (c-HDL) level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get c-HDL level

    Time frame: Baseline to week 13 (end of intervention)

  7. Low density lipoprotein (c-LDL)

    Low density lipoprotein (c-LDL) level will be calculated at baseline and week 13 with Friedewald formula to get c-LDL level

    Time frame: Baseline to week 13 (end of intervention)

  8. Very low density lipoprotein (VLDL)

    Very low density lipoprotein (VLDL) level will be calculated at baseline and week 13 with triglycerides concentration/5 formula to get VLDL level

    Time frame: Baseline to week 13 (end of intervention)

  9. Fasting blood triglycerides concentration

    Fasting blood triglycerides concentration level will be evaluated at baseline and week 13 by enzymatic- colorimetric technique to get triglycerides concentration

    Time frame: Baseline to week 13 (end of intervention)

  10. Concentration of blood creatinine

    Concentration of blood creatinine level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get creatinine level

    Time frame: Baseline to week 13 (end of intervention)

  11. Concentration of blood alanine aminostranferase (ALT)

    Concentration of blood alanine aminostranferase level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get ALT level

    Time frame: Baseline to week 13 (end of intervention)

  12. Concentration of blood aspartate aminostranferase (AST)

    Concentration of blood aspartate aminostranferase level will be evaluated at baseline and week 13 by enzymatic-colorimetric technique to get AST level

    Time frame: Baseline to week 13 (end of intervention)

  13. Incidence of treatment-Emergent Adverse Events

    Incidence of treatment-Emergent Adverse Events of probiotics+placebo or metformin will be identified by clinical evaluation from baseline week to week 13 with continuous surveiilance

    Time frame: Baseline to week 13 (continuous surveiilance)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2027, 98 months after the start.

Of 27 phase 2 interventional studies under Prediabetic State, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 69. This study's planned 98 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jun 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2020
First posted
Apr 10, 2020
StartActual
Oct 24, 2019
Primary completionEst.
Dec 2027was Jun 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Dec 2027
Oct 7, 2026
Study completion
Dec 2026→Dec 2027
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Jun 2026→Dec 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04341571
Lead sponsor
University of Guadalajara
Responsible party
Karina Griselda Pérez Rubio (Principal Investigator, University of Guadalajara) — Principal investigator
First posted
Apr 10, 2020
Start date
Oct 24, 2019
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

KARINA G PÉREZ-RUBIO, PhD
principal investigator · University of Guadalajara

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion